Publications by authors named "Min-Hee Hong"

Claim this Profile
I
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Danny Rischin, Aaron R Hansen, Ezra E W Cohen, Makoto Tahara, Kevin J Harrington, Min Hee Hong

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preoperative chemoradiotherapy plus pembrolizumab for esophageal squamous cell carcinoma (ACTS-29).
Min Hee Hong, Sung Kwan Shin, Su-Jin Choi, Beung-Chul Ahn, Hye Ryun Kim

Esophagus· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC.
Myung-Ju Ahn, Aaron Lisberg, Yasushi Goto, Jacob Sands, Min Hee Hong, Hong Zebger-Gong

J Thorac Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma.
Min Hee Hong, Seoyoung Lee, Chang Gon Kim, Wonrak Son, Jin Woo Park, Hyun Jun Hong

Oral Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial.
Kyoo Hyun Kim, Shinwon Hwang, Min Kyoung Kim, Keon-Uk Park, Tak Yun, Min Hee Hong

Cancer Res Treat· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-1BB Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy.
Junha Cha, Chang Gon Kim, Nam Suk Sim, Gamin Kim, Wonrak Son, Hyun Jun Hong, Min Hee Hong

Cell Rep Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Response to the Letter to the Editor Regarding "Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations".
Min Hee Hong

J Thorac Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial.
Sehhoon Park, Hee Kyung Ahn, Seoyoung Lee, Young Joo Min, Jinyong Kim, Min Hee Hong

J Thorac Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating advanced lung cancer care, patient-physician alliance, cancer stigma, and psychosocial support in Asia-Pacific: perspectives from patients, caregivers, and physicians.
Chee Khoon Lee, Xue Yang, Yasushi Goto, Kang Yun Lee, Hyung Seok Yim, Min Hee Hong

Future Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative single-cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses.
Seungbyn Baek, Junha Cha, Min Hee Hong, Gamin Kim, Yoon Woo Koh

Cancer Commun (Lond)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes and Biomarker Analysis Based on Routine Clinical, Laboratory, and Pathologic Parameters in Metastatic or Unresectable Esophageal Cancer Treated with First-Line Anti-PD-1 Plus Fluoropyrimidine and Platinum.
Jiyun Jeong, Seyoung Seo, Sung-Bae Kim, Joon Seon Song, Hye Ryun Kim, Moonki Hong, Min Hee Hong

Cancers (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commentary: Real-World Insights into Adjuvant Immunotherapy after Esophagectomy.
Min Hee Hong

J Chest Surg· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of thyroid radiation dose with thyroid dysfunction in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy followed by maintenance immunotherapy.
Gowoon Yang, Hong In Yoon, Sun Min Lim, Min Hee Hong, Jaeho Cho

Lung Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA).
Jii Bum Lee, Su-Jin Choi, Hyo Sup Shim, Byung Jo Park, Chang Young Lee, Min Hee Hong

J Thorac Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours.
Timothy Price, Iwona Lugowska, Sant P Chawla, Gerald Falchook, Vivek Subbiah, Min Hee Hong

BMJ Open· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell multi-omics reveals tumor microenvironment factors underlying poor immunotherapy responses in ALK-positive lung cancer.
Seungbyn Baek, Euijeong Sung, Gamin Kim, Min Hee Hong, Chang Young Lee

Cancer Commun (Lond)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.
Dong Kwon Kim, Chun-Bong Synn, Wongeun Lee, Ha-Ni Jo, Chai Young Lee, Min Hee Hong

Mol Cancer Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC.
Seung Yeon Oh, Sewon Park, Seoyoung Lee, Eun Ji Lee, Tae Ho Kim, Min Hee Hong

Cell Rep Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
Myung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares, Robin Cornelissen, Nicolas Girard, Min Hee Hong

J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy.
Chan Yeong Kim, Dong Jin Park, Beung Chul Ahn, Seungbyn Baek, Min Hee Hong, Hong In Yoon

Nat Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiomics and PD-L1 expression predict immunotherapy benefits in patients with head and neck squamous cell carcinoma.
Yongsik Sim, Beomseok Sohn, Sooyon Kim, Hye Ryun Kim, Min Hee Hong

Future Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial.
Min Hee Hong, Yoon Ji Choi, Hee Kyung Ahn, Sun Min Lim, Bhumsuk Keam

JAMA Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea.
Joo Sung Shim, Youhyun Kim, Taeho Yuh, Jii Bum Lee, Hye Ryun Kim, Min Hee Hong

Lung Cancer (Auckl)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant chemotherapy followed by definitive local treatment in locally advanced sinonasal squamous cell carcinoma.
Jina Kim, Min Hee Hong, Hye Ryun Kim, Sun Min Lim, Chang Gon Kim, Hyun Jun Hong

Front Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12).
Dong Ki Lee, Sook Ryun Park, Yeul Hong Kim, Yun-Gyoo Lee, Su-Jin Shin, Min Hee Hong

Oncoimmunology· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis